Filtering by:
Salivary Gland CancerTop Story
November 28, 2018
FDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
March 22, 2016
ACS Releases Long-term Care Guideline for Survivors of Head and Neck Cancer
ACS Releases Long-term Care Guideline for Survivors of Head and Neck Cancer
